Best Anal Cancer Doctors in Hyderabad — CION's Dedicated Anal Cancer Panel

Unlike most cancers, anal cancer is treated primarily by radiation oncology and medical oncology — not surgery. The best doctor is a radiation oncologist with experience in IMRT-based pelvic chemoradiation, paired with a medical oncologist current with the Nigro protocol (5-FU plus mitomycin C with concurrent radiation). Surgery (APR) is reserved only for chemoradiation failures. At CION, every anal cancer case is reviewed by a multidisciplinary tumour board, with radiation oncology led by Dr. Kirti Ranjan Mohanty and medical oncology by Dr. Naresh Gundu.

Yes — in most cases. Since 1974, the Nigro protocol (concurrent chemotherapy plus radiation) has replaced surgery as the standard of care for anal squamous cell carcinoma. Complete response rates are around 75–80% with current protocols, meaning the majority of patients avoid surgery entirely and keep their sphincter and bowel function. Abdominoperineal resection (APR) with permanent colostomy is now reserved as a salvage operation for patients who do not respond to chemoradiation. Centres that still default to upfront surgery for anal cancer are practising 50 years behind standard of care.

The Nigro protocol is the standard chemoradiation treatment for anal squamous cell carcinoma, developed by Dr. Norman Nigro in the mid-1970s. It combines radiation therapy (currently around 50 Gy delivered using IMRT) with concurrent chemotherapy — 5-fluorouracil (5-FU) and mitomycin C — over approximately 5–6 weeks. An alternative regimen uses oral capecitabine instead of 5-FU. The protocol produces complete response in approximately 75–80% of patients, sparing them surgery and permanent colostomy. Modern delivery uses IMRT to spare surrounding tissues and reduce side effects. CION delivers the Nigro protocol with modern IMRT planning across all anal cancer cases.

Yes — pelvic radiation for anal cancer can affect all three. Acute side effects (during and shortly after treatment) include radiation dermatitis, diarrhoea, painful bowel movements, and fatigue. Long-term effects can include sphincter function changes, sexual dysfunction (vaginal stenosis in women, erectile dysfunction in men), infertility (significant in younger patients), and a small risk of fractures in the pelvic bones. Modern IMRT meaningfully reduces toxicity compared to older radiation techniques by targeting only the tumour and sparing the surrounding tissue. CION uses IMRT for all anal cancer cases and provides supportive care throughout treatment to manage acute side effects.

Most likely, yes. Over 90% of anal cancers are caused by human papillomavirus (HPV) — primarily HPV-16, the same high-risk strain that causes most cervical cancers. HPV infection is extremely common and most people clear it without ever developing cancer; in a small subset, persistent infection over many years causes cellular changes that lead to cancer. This is not a reflection on you or your behaviour. HPV is transmitted through any close contact (not necessarily sexual contact specifically), and most adults have been exposed to HPV at some point. Discuss with your doctor whether your partner or family members should consider HPV-related screening.

HPV is so common that routine HPV testing of partners or family is not recommended in the same way that, say, HIV testing would be after exposure. However, women in your household should follow standard cervical cancer screening guidelines (cervical pap smear). For those with risk factors for anal cancer, anal pap smear or high-resolution anoscopy may be considered. HPV vaccination is increasingly recommended for adolescents and young adults regardless of family history. Your CION oncologist can discuss specific recommendations for your family.

An oncologist — specifically, a radiation oncologist with chemoradiation experience and a medical oncologist with concurrent chemotherapy experience. A colorectal or general surgeon may have been the first to perform the biopsy that confirmed cancer, but surgery is no longer the primary treatment for anal cancer. Treatment must be led by radiation and medical oncology. A surgical oncologist is needed only as a salvage option if chemoradiation fails.

Approximately 20–25% of patients have residual or recurrent disease after Nigro protocol chemoradiation. For these patients, salvage surgery — typically abdominoperineal resection (APR) with permanent colostomy — is offered. Salvage APR has acceptable long-term survival in well-selected patients. The decision to proceed with salvage surgery is made at the multidisciplinary tumour board after careful re-staging, usually 6–8 weeks after completing chemoradiation. CION's GI surgical oncology team performs salvage APR when needed.

A second opinion is especially valuable for anal cancer — particularly if you've been offered upfront surgery without chemoradiation being seriously discussed, which would not be the current standard of care. At CION the second opinion is free, written, and yours to keep — our multidisciplinary tumour board reviews your biopsy, imaging, and existing recommendation and provides a documented opinion you can take anywhere.

Costs vary by stage and treatment. Chemoradiation (Nigro protocol) over 5–6 weeks ranges approximately ₹3,00,000 to ₹6,00,000 including IMRT, concurrent 5-FU or capecitabine plus mitomycin C, and supportive care. Salvage APR (if chemoradiation fails) ranges ₹3,00,000 to ₹6,00,000 additional. Immunotherapy (pembrolizumab or nivolumab) for advanced or recurrent disease is significantly higher per cycle. For a detailed cost breakdown by treatment type, see our anal cancer treatment in Hyderabad page. Every CION patient receives a written, itemised cost estimate before treatment begins. Aarogyasri, EMI, and cashless insurance are accepted.